GSK (GSK) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the ...

GSK's CEO Emma Walmsley will step down in December and be replaced by insider Luke Miels, the British drugmaker said on Monday, tasking the new leader to deliver shareholder value and prepare for the ...

CEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over £31 billion, with specialty ...

LONDON, Oct 29 (Reuters) - GSK (GSK.L), opens new tab raised its 2025 sales and earnings forecasts on Wednesday as its speciality HIV and cancer drugs posted double digit growth, lifting the British ...

GSK plc (NYSE: GSK) appointed Luke Miels as the CEO Designate of GSK. He will assume full responsibility as CEO and join the Board on January 1, 2026. He joined GSK in 2017 and is currently Chief ...

GSK raised its full-year financial outlook despite mixed results from its vaccines segment and declining sales of Shingrix. The British pharma giant reported total quarterly sales of £7.9 billion, up ...

Unknown litigation costs have cast a cloud over wide-moat GSK GSK since 2020, when the US Food and Drug Administration requested that Zantac be taken off the market. But earlier this month, GSK ...

LONDON, Jan 7 (Reuters) - GSK (GSK.L), opens new tab will use promising results from two studies of its experimental chronic hepatitis B therapy to support planned regulatory applications, it said on ...

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation unjustified, leading to a "Strong Buy" rating. The company’s diversified portfolio ...